Aspergilosis. Formas clínicas y tratamiento

Segal, 2009, Aspergillosis, N Engl J Med, 360, 1870, 10.1056/NEJMra0808853 Agarwal, 2009, Allergic bronchopulmonary aspergillosis, Chest, 135, 805, 10.1378/chest.08-2586 Balajee, 2006, Phenotypic and genotypic identification of human pathogenic aspergilli, Future Microbiol, 1, 435, 10.2217/17460913.1.4.435 O’Gorman, 2009, Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus, Nature, 457, 471, 10.1038/nature07528 Van Assen, 2000, Aspergillus tracheobronchitis after allogeneic bone marrow transplantation, Bone Marrow Transplant, 26, 1131, 10.1038/sj.bmt.1702679 Sivak-Callcott, 2004, Localised invasive sino-orbital aspergillosis: characteristic features, Br J Ophthalmol, 88, 681, 10.1136/bjo.2003.021725 El-Hamamsy, 2005, Aspergillus endocarditis after cardiac surgery, Ann Thorac Surg, 80, 359, 10.1016/j.athoracsur.2004.08.070 González-Vicent, 2008, Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis, Transpl Infect Dis, 10, 193, 10.1111/j.1399-3062.2007.00288.x Fortún, 2011, Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) Update], Enferm Infecc Microbiol Clin, 29, 435, 10.1016/j.eimc.2011.01.010 García-Vidal, 2008, Epidemiology of invasive mold infections in allogeneic stem-cell transplant recipients: biological risk factors for infection according to time after transplantation, Clin Infect Dis, 47, 1041, 10.1086/591969 Ferwerda, 2009, Human dectin-1 deficiency and mucocutaneous fungal infections, N Engl J Med, 361, 1760, 10.1056/NEJMoa0901053 Bochud, 2008, Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation, New Engl J Med, 359, 1766, 10.1056/NEJMoa0802629 Pappas, 2010, Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET), Clin Infect Dis, 50, 1101, 10.1086/651262 Gavalda, 2005, Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study, Clin Infect Dis, 41, 52, 10.1086/430602 Fortun, 2002, Risk factors for invasive aspergillosis in liver transplant recipients, Liver Transpl, 8, 1065, 10.1053/jlts.2002.36239 Gavaldà, 2007, Infection in lung transplantation, Enferm Infecc Microbiol Clin, 25, 639, 10.1157/13112940 Garnacho-Montero, 2005, Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome, Crit Care, 9, R191, 10.1186/cc3488 Vandewoude, 2006, Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients, Crit Care, 10, R31, 10.1186/cc4823 Bulpa, 2007, Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease, Eur Respir J, 30, 782, 10.1183/09031936.00062206 Lambourne, 2009, Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients, Clin Infect Dis, 49, 1486, 10.1086/644619 Ascioglu, 2002, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin Infect Dis, 34, 7, 10.1086/323335 De Pauw, 2008, Clin Infect Dis, 46, 1813, 10.1086/588660 Pfeiffer, 2006, Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis, Clin Infect Dis, 42, 1417, 10.1086/503427 Fortun, 2001, Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients, Transplantation, 71, 145, 10.1097/00007890-200101150-00023 Aubry, 2006, Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders, J Clin Microbiol, 44, 389, 10.1128/JCM.44.2.389-394.2006 Fortún, 2009, False-positive results of Aspergillus galactomannan antigenemia in liver transplant recipients, Transplantation, 87, 256, 10.1097/TP.0b013e31819288d5 Stevens, 2003, Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference, Clin Infect Dis, 37, S225, 10.1086/376525 Park, 2011, Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma, Clin Infect Dis, 52, e149, 10.1093/cid/cir027 Alcazar-Fuoli, 2008, Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification, Antimicrob Agents Chemother, 52, 1244, 10.1128/AAC.00942-07 Verweij, 2007, Multiple-triazole-resistant aspergillosis, N Engl J Med, 356, 1481, 10.1056/NEJMc061720 Snelders, 2009, Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles, Appl Environ Microbiol, 75, 4053, 10.1128/AEM.00231-09 Arendrup, 2010, Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence, PLoS One, 5, e10080, 10.1371/journal.pone.0010080 Walsh, 2008, Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America, Clin Infect Dis, 46, 327, 10.1086/525258 Herbrecht, 2002, Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis, N Engl J Med, 347, 408, 10.1056/NEJMoa020191 Cornely, 2007, Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial), Clin Infect Dis, 44, 1289, 10.1086/514341 Viscoli, 2009, An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients, J Antimicrob Chemother, 64, 1274, 10.1093/jac/dkp355 Herbrecht, 2010, Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study, Bone Marrow Transplant, 45, 1227, 10.1038/bmt.2009.334 Maertens, 2004, Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy, Clin Infect Dis, 39, 1563, 10.1086/423381 Walsh, 2007, Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial, Clin Infect Dis, 44, 2, 10.1086/508774 Kontoyiannis, 2009, Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis, Transpl Infect Dis, 11, 89, 10.1111/j.1399-3062.2008.00349.x Marr, 2004, Combination antifungal therapy for invasive aspergillosis, Clin Infect Dis, 39, 797, 10.1086/423380 Singh, 2006, Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study, Transplantation, 81, 320, 10.1097/01.tp.0000202421.94822.f7 Caillot, 2007, Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (COMBISTRAT trial), Cancer, 110, 2740, 10.1002/cncr.23109 Ostrosky-Zeichner, 2008, Combination antifungal therapy: a critical review of the evidence, Clin Microbiol Infect, 14, 65, 10.1111/j.1469-0691.2008.01983.x Schwartz, 2005, Improved outcome in central nervous system aspergillosis, using voriconazole treatment, Blood, 106, 2641, 10.1182/blood-2005-02-0733 Bandera, 2008, Interferon-gamma and granulocyte-macrophage colony stimulating factor therapy in three patients with pulmonary aspergillosis, Infection, 36, 368, 10.1007/s15010-008-7378-7 Saad, 2006, Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants, Pharmacotherapy, 26, 1730, 10.1592/phco.26.12.1730 Mathis, 2004, Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases, Transplant Proc, 36, 2708, 10.1016/j.transproceed.2004.09.043 Sable, 2002, Safety and tolerability of caspofungin acetate in the treatment of fungal infections, Transpl Infect Dis, 4, 25, 10.1034/j.1399-3062.2002.01004.x Chandrasekar, 2006, Micafungin: a new echinocandin, Clin Infect Dis, 42, 1171, 10.1086/501020 Karlsson, 2009, Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies, Antimicrob Agents Chemother, 53, 935, 10.1128/AAC.00751-08 Walsh, 2002, Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children, Pediatr Infect Dis J, 21, 240, 10.1097/00006454-200203000-00015 Denning, 2003, Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review, Clin Infect Dis, 37, S265, 10.1086/376526 Lebecque, 2009, Omalizumab for treatment of ABPA exacerbations in CF patients, Pediatr Pulmonol, 44, 516, 10.1002/ppul.21002 Tillie-Leblond, 2011, Allergic bronchopulmonary aspergillosis and omalizumab, Allergy, 66, 1254, 10.1111/j.1398-9995.2011.02599.x